These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 33157919)

  • 1. Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report.
    Jin F; Yang M; Chen Y; Jiang L; Liu L
    Medicine (Baltimore); 2020 Nov; 99(45):e22632. PubMed ID: 33157919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
    Oiwa K; Morita M; Kishi S; Okura M; Tasaki T; Matsuda Y; Tai K; Hosono N; Ueda T; Yamauchi T
    Anticancer Res; 2016 Dec; 36(12):6655-6662. PubMed ID: 27919998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib-associated tumor lysis syndrome.
    Shely RN; Ratliff PD
    Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.
    Steiner RE; Orlowski RZ; Lee HC
    Acta Haematol; 2018; 139(1):67-70. PubMed ID: 29402766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
    Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
    Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute kidney injury in bortezomib-treated patients with multiple myeloma.
    Song SM; Jeon J; Jang HR; Kim K; Huh W; Kim YG; Lee JE
    Nephrol Dial Transplant; 2023 Aug; 38(9):2077-2085. PubMed ID: 36662030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
    Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
    Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
    N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
    J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.
    Terzi Demirsoy E; Birtas Atesoglu E; Eren N; Gedük A; Mehtap O; Tarkun P; Hacıhanefioğlu A
    Tumori; 2019 Dec; 105(6):NP24-NP27. PubMed ID: 30580656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
    Sokol J; Guman T; Chudej J; Hlebaskova M; Stecova N; Valekova L; Kucerikova M; Stasko J
    Ann Hematol; 2022 Jan; 101(1):81-89. PubMed ID: 34550463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
    Kumar SK; LaPlant BR; Reeder CB; Roy V; Halvorson AE; Buadi F; Gertz MA; Bergsagel PL; Dispenzieri A; Thompson MA; Crawley J; Kapoor P; Mikhael J; Stewart K; Hayman SR; Hwa YL; Gonsalves W; Witzig TE; Ailawadhi S; Dingli D; Go RS; Lin Y; Rivera CE; Rajkumar SV; Lacy MQ
    Blood; 2016 Nov; 128(20):2415-2422. PubMed ID: 27702799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
    Mina R; Falcone AP; Bringhen S; Liberati AM; Pescosta N; Petrucci MT; Ciccone G; Capra A; Patriarca F; Rota-Scalabrini D; Bonello F; Musolino C; Cea M; Zambello R; Tacchetti P; Belotti A; Cellini C; Paris L; Grasso M; Aquino S; De Paoli L; De Sabbata G; Ballanti S; Offidani M; Boccadoro M; Monaco F; Corradini P; Larocca A
    Blood Cancer J; 2021 Dec; 11(12):197. PubMed ID: 34876566
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
    Sanagawa A; Hotta Y; Kondo M; Nishikawa R; Tohkin M; Kimura K
    Anticancer Drugs; 2020 Feb; 31(2):183-189. PubMed ID: 31789626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
    Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
    BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma.
    Ohashi Y; Yatabe M; Niijima D; Tani K; Ogawa C; Yachi Y; Kagoo T; Boku S; Ueno H; Yano T; Higai K; Yokoyama A
    In Vivo; 2020; 34(5):2821-2828. PubMed ID: 32871820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
    Dimopoulos MA; Grosicki S; Jędrzejczak WW; Nahi H; Gruber A; Hansson M; Gupta N; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
    Eur J Cancer; 2019 Jan; 106():89-98. PubMed ID: 30471652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
    Suzuki K; Terui Y; Nishimura N; Ueda K; Mishima Y; Sakajiri S; Yokoyama M; Aiba K; Hatake K
    Jpn J Clin Oncol; 2014 May; 44(5):435-41. PubMed ID: 24664944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.